HIV에 사는 사람들의 바이러스 저수지의 크기와 활동을 줄이기 위해 FTR (Fostemsavir) (FTR)이 있거나없는 VH3810109의 사용을 조사하는 연구 (ENTRANCE)
탐색 적 단계 1B, 다기관, 무작위 화, 공개 라벨 연구는 HIV-1과 함께 살고있는 성인의 바이러스 저수지에 대한 인테그라 제 억제제 기반 항 레트로 바이러스 요법과 함께 구강 푸스 세비 르의 정맥 내 VH3810109의 투여의 영향을 조사하기위한 탐색 적입니다.
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Rotterdam, 네덜란드, 3015 GD
- GSK Investigational Site
-
-
-
-
Capital Region
-
Hvidovre, Capital Region, 덴마크, 2650
- GSK Investigational Site
-
-
Central Jutland
-
Aarhus N, Central Jutland, 덴마크, 8200
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield, California, 미국, 93309
- GSK Investigational Site
-
San Diego, California, 미국, 92103
- GSK Investigational Site
-
-
Florida
-
Ft. Pierce, Florida, 미국, 34982-7148
- GSK Investigational Site
-
Orlando, Florida, 미국, 32803-1851
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- GSK Investigational Site
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- GSK Investigational Site
-
St Louis, Missouri, 미국, 63110
- GSK Investigational Site
-
-
New York
-
New York, New York, 미국, 10032
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45267
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, 미국, 15213
- GSK Investigational Site
-
-
Texas
-
Dallas, Texas, 미국, 75246-2004
- GSK Investigational Site
-
Dallas, Texas, 미국, 75208-4599
- GSK Investigational Site
-
-
-
-
-
Brussels, 벨기에, 1000
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, 벨기에, 9000
- GSK Investigational Site
-
-
-
-
-
Barcelona, 스페인, 08036
- GSK Investigational Site
-
Barcelona, 스페인, 08035
- GSK Investigational Site
-
Barcelona, 스페인, 08003
- GSK Investigational Site
-
Barcelona, 스페인, 8907
- GSK Investigational Site
-
Barcelona, 스페인, 08026
- GSK Investigational Site
-
Barcelona, 스페인, 08916
- GSK Investigational Site
-
Córdoba, 스페인, 14004
- GSK Investigational Site
-
La Laguna Santa Cruz, 스페인, 38320
- GSK Investigational Site
-
Madrid, 스페인, 28041
- GSK Investigational Site
-
Madrid, 스페인, 28040
- GSK Investigational Site
-
Madrid, 스페인, 28046
- GSK Investigational Site
-
Madrid, 스페인, 28034
- GSK Investigational Site
-
Madrid, 스페인, 28031
- GSK Investigational Site
-
Madrid, 스페인, 28020
- GSK Investigational Site
-
Palma de Mallorca, 스페인, 07120
- GSK Investigational Site
-
Palma de Mallorca, 스페인, 7198
- GSK Investigational Site
-
Seville, 스페인, 41013
- GSK Investigational Site
-
Valencia, 스페인, 46026
- GSK Investigational Site
-
Valencia, 스페인, 46014
- GSK Investigational Site
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, 스페인, 28224
- GSK Investigational Site
-
-
-
-
-
London, 영국, SE1 7EH
- GSK Investigational Site
-
London, 영국, NW3 2QG
- GSK Investigational Site
-
London, 영국, W2 1NY
- GSK Investigational Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
AGE
• Age between 18 years and 70 years old at the time of obtaining informed consent.
SEX AND GENDER • Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.
PARTICIPANT KEY CHARACTERISTICS • Participant has a documented diagnosis of HIV-1 infection. Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.
Population 1 only:
- Plasma HIV-1 RNA >=2000 copies/milliliter (c/mL) at Screening.
- CD4+ T cell count >=300 cells/microliter (μL) at Screening.
- Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.
Population 2 only:
- Participant is stably virologically suppressed (plasma HIV-1 RNA <50 c/mL).
- Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
- CD4+ T cell count >=450 cells/μL at Screening.
WEIGHT
• Body weight >=50 kg to <=115 kg.
INFORMED CONSENT • Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.
Exclusion Criteria:
CONCURRENT MEDICAL CONDITIONS & MEDICAL HISTORY
- Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
- Participant has documented diagnosis of HIV-2 infection.
- Participant is known to have acquired HIV via perinatal transmission.
- Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
- Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
- Ongoing or clinically relevant pancreatitis.
- Current HIV-related kidney disease.
- History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.
CARDIAC & CARDIOVASCULAR CONDITIONS
- Participants who are at clinically significant risk of cardiovascular disease.
- Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
- Confirmed QTcF value outside normal range at Screening or Day 1.
HEPATIC CONDITIONS
- History of clinically relevant hepatitis in the 6 months prior to Screening.
- Participants with severe hepatic impairment.
- Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
- Unstable liver disease.
- History of liver cirrhosis with or without hepatitis viral co-infection.
NEUROPSYCHIATRIC CONDITIONS • Participants who pose a significant suicide risk.
LABORATORY DIAGNOSTIC ASSESSMENTS
- Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
- Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
- Alanine transferase (ALT) >=3 times the upper limit of normal (ULN) at Screening.
- Estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m^2.
- Hemoglobin >=Grade 2 at Screening.
- Platelets >=Grade 2 at Screening.
- Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
- Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.
Population 2 only:
• Two or more plasma HIV-1 RNA results >=50 c/mL in the 18 months prior to Screening.
INFECTIOUS DISEASES
- Active hepatitis B virus (HBV) co-infection.
- Active hepatitis C virus (HCV) co-infection.
- Participant has untreated syphilis before enrolment.
- Known history of active Mycobacterium TB disease (regardless of treatment status).
ANTIRETROVIRAL RESISTANCE • Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.
PRIOR AND CONCOMITANT MEDICATIONS
-
Prior use of any of the following agents:
- long-acting ARVs (any dose in the past 24 months or within 5 half-lives [whichever is longer])
- FTR (any lifetime use)
- HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)
- HIV-1 monoclonal antibody therapy (any lifetime use).
-
Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.
-
History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.
-
Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.
-
Treatment with any of the following agents within 30 days of enrolment:
- radiation therapy
- cytotoxic chemotherapeutic agents
- anti-tuberculosis therapy
- immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
-
Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.
Population 1 only:
• Known use of PrEP or PEP within <30 days (for oral agents) or <52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result >=30 days after the last dose of oral PrEP or PEP (or >=52 weeks after the last dose of LA PrEP) are not excluded.
Population 2 only:
• Current use of NNRTI-containing ART.
OTHER EXCLUSIONS
- History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
- Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
- Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
- Participant is currently participating in, or anticipates being selected for, any other interventional study.
- Participant is known or suspected to be an HIV long-term non-progressor or elite controller, based on historical off-treatment plasma HIV-1 RNA results.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Participants receiving SOC INSTI-based ART in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. |
|
실험적: Participants receiving SOC INSTI-based ART+VH3810109 in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
다른 이름들:
|
|
실험적: Participants receiving SOC INSTI-based ART+VH3810109+FTR in Randomized Intervention Phase (Step 1)
|
A SOC INSTI-based ART regimen will be administered. VH3810109 will be administered.
다른 이름들:
Fostemsavir will be administered.
다른 이름들:
|
|
실험적: Participants receiving VH3810109 in ATI Phase (Step 2)
|
VH3810109 will be administered.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cells
기간: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Randomized Intervention Phase (Step 1): Change from baseline in total, intact, and defective proviral HIV-1 DNA per million CD4+ T cells
기간: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute change in cell-associated HIV-1 RNA/proviral DNA ratios in CD4+ T cells
기간: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Absolute values for HIV-1-specific CD8+ T cell count
기간: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Change from baseline in HIV-1-specific CD8+ T cell count
기간: From Baseline (Day 1) to Month 12
|
From Baseline (Day 1) to Month 12
|
|
Randomized Intervention Phase (Step 1): Number of participants with Grade 3 and Grade 4 adverse events (AEs)
기간: From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
Randomized Intervention Phase (Step 1): Number of participants with serious adverse events (SAEs), deaths and AEs leading to discontinuation of study intervention
기간: From Baseline (Day 1) to Month 15
|
From Baseline (Day 1) to Month 15
|
|
ATI Phase (Step 2): Time to ART restart
기간: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with Grade 3 and Grade 4 AEs
기간: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with SAEs and deaths
기간: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
|
ATI Phase (Step 2): Number of participants with disease progression (HIV-associated conditions, acquired immunodeficiency syndrome [AIDS] and death)
기간: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 221794
- 2025-520629-19-00 (기타 식별자: EU CT Number)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf
IPD 공유 기간
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 공유 액세스 기준
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .